Psycho-oncology

Harvard Review of Psychiatry

Volumn 17, Issue 6, 2009, Pages 361-376

  Breitbart, William S ^a,b   Alici, Yesne ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Central Regional Hospital   (United States)

Author keywords

Psychiatric care of cancer patients; Psycho oncology; Psychosocial care of cancer patients

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ARIPIPRAZOLE; ASPARAGINASE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BLEOMYCIN; CARMUSTINE; CHLORPROMAZINE; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYPROTERONE; FLUOROURACIL; GLUCOCORTICOID; GRANISETRON; HALOPERIDOL; IFOSFAMIDE; INTERFERON; METHOTREXATE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PROCARBAZINE; QUETIAPINE; RISPERIDONE; TAMOXIFEN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ZIPRASIDONE;

ACUTE STRESS DISORDER; ADJUSTMENT DISORDER; ANXIETY DISORDER; BEREAVEMENT; CANCER FATIGUE; CANCER RESEARCH; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; DELIRIUM; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISTRESS SYNDROME; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; GENERALIZED ANXIETY DISORDER; HEALTH CARE PERSONNEL; HUMAN; MAJOR DEPRESSION; MEDICAL ASSESSMENT; MENTAL DISEASE; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SUICIDE;

ADAPTATION, PSYCHOLOGICAL; COMORBIDITY; COOPERATIVE BEHAVIOR; FORECASTING; HUMANS; INTERDISCIPLINARY COMMUNICATION; MENTAL DISORDERS; NEOPLASMS; PATIENT CARE TEAM; PSYCHIATRY; PSYCHOSOMATIC MEDICINE; PSYCHOTROPIC DRUGS; REFERRAL AND CONSULTATION; SICK ROLE; SOCIAL SUPPORT; SPECIALIZATION; SUICIDE;

EID: 72049088801     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673220903465700     Document Type: Review

References (118)

1. Holland JC. History of psycho-oncology: overcoming attitudinal and conceptual barriers. Psychosom Med 2002;64:206-221
2. Holland JH, Friedlander MM. Oncology. In: Blumenfield M, Strain JJ, eds. Psychosomatic medicine. Philadelphia, Ontario: Lippincott Williams & Wilkins, 2006.
3. Holland JC, Gooen-Piels J. Psycho-oncology. In: Holland JC, Frei E, eds. Cancer medicine. 6th ed. Hamilton, BC Decker, 2003.
4. Bylund CL, Brown RF, Di Ciccone BL, et al. Training faculty to facilitate communication skills training: development and evaluation of a workshop. Patient Educ Couns 2008;70: 430-436
5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: distress management. Ver. 1. 2010. http://www.nccn.org/professionals/ physiciangls/PDF/distress.pdf
6. Snyder DC, Morey MC, Sloane R, et al. Reach out to ENhancE Wellness in Older Cancer Survivors (RENEW): design, methods and recruitment challenges of a home-based exercise and diet intervention to improve physical function among long-term survivors of breast, prostate, and colorectal cancer. Psychooncology 2009;18:429-439
7. Breitbart W, Lederberg MS, Rueda-Lara M, Alici Y. Psychooncology. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's synopsis of psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2009.
8. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26: 643-652
9. Jacobson CM, Rosenfeld B, Pessin H, Breitbart W. Depression and IL-6 blood plasma concentrations in advanced cancer patients. Psychosomatics 2008;49:64-66
10. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485-493
11. Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst 2004;32:150-157
12. Winell J, Roth AJ. Psychiatric assessment and symptom management in elderly cancer patients. Oncology (Williston Park) 2005;19:1479-1490
13. Breitbart W, Gibson C, Poppito SR, Berg A. Psychotherapeutic interventions at the end of life: a focus on meaning and spirituality. Can J Psychiatry 2004;49:366-372
14. Daniels J, Kissane DW. Psychosocial interventions for cancer patients. Curr Opin Oncol 2008;20:367-371
15. Breitbart W, Rosenfeld B, Gibson C, et al. Meaning-centered group psychotherapy for patients with advanced cancer: a pilot randomized controlled trial. Psychooncology. 2009 Mar 9 [Epub ahead of print].
16. Lengacher CA, Johnson-Mallard V, Post-White J, et al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psychooncology. 2009 Feb 20 [Epub ahead of print].
17. Jacobsen PB. Promoting evidence-based psychosocial care for cancer patients. Psychooncology 2009;18:6-13.
18. Derogatis LR, Morrow GR, Fetting D, et al. The prevalence of psychiatric disorders among cancer patients. JAMA 1983;249:751-757
19. Park C, Folkman S. Meaning in the context of stress and coping. Rev Gen Psychol 1997;1:115-144
20. Li J, Johansen C, Hansen D, Olsen J. Cancer incidence in parents who lost a child: a nationwide study in Denmark. Cancer 2002;95:2237-2242
21. Petticrew M, Bell R, Hunter D. Influence of psychological coping on survival and recurrence in people with cancer: systematic review BMJ 2002;325:1066-1075
22. Schapiro IR, Nielsen LF, Jørgensen T, Boesen EH, Johansen C. Psychic vulnerability and the associated risk for cancer. Cancer 2002;94:3299-3306
23. Hansen PE, Floderus B, Frederiksen K, Johansen C. Personality traits, health behavior, and risk for cancer: a prospective study of Swedish twin court. Cancer 2005;103:1082-1091
24. Bergelt C, Christensen J, Prescott E, Grønbaek M, Koch U, Johansen C. Vital exhaustion and risk for cancer: a prospective cohort study on the association between depressive feelings, fatigue, and risk of cancer. Cancer 2005;104:1288-1295
25. Dalton SO, Boesen EH, Ross L, Schapiro IR, Johansen C. Mind and cancer: do psychological factors cause cancer? Eur J Cancer 2002;38:1313-1323
26. Rowland JH. Interpersonal resources: developmental stage of adaptation: adult model. In: Holland JC, Rowland JH, eds. Handbook of psycho-oncology: psychological care of the patient with cancer. New York: Oxford University Press, 1989.
27. Marmot M. Social determinants of health inequalities. Lancet 2005;365:1099-1104
28. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004;32:57-71.
29. Chochinov HM, Wilson KG, Enns M, Lander S. Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am J Psychiatry 1994;151:537-540
30. Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Intern Med 2001;135:32-40.
31. Breitbart W, Alici Y. Agitation and delirium at the end of life: "We couldn't manage him." JAMA 2008;300:2898-2910
32. Holland JC, Andersen B, Breitbart WS, et al. Distress management. J Natl Compr Canc Netw 2007;5:66-98.
33. Adler NE, Page NEK, eds. Cancer care for the whole patient: meeting psychosocial health needs.Washington, DC: National Academies, 2008.
34. Moorey S, Greer S, Watson M, et al. Adjuvant psychological therapy for patients with cancer: outcome at one year. Psychooncology 1994;3:39-46.
35. Gielissen MF, Verhagen CA, Bleijenberg G. Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up. Br J Cancer 2007;97:612-618
36. Kissane DW, Grabsch B, Clarke DM, et al. Supportiveexpressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology 2007;16:277-286
37. Kissane DW, Bloch S, Smith GC, Miach P, et al. Cognitiveexistential group psychotherapy for women with primary breast cancer: a randomised controlled trial. Psycho-Oncology 2003;12:532-546
38. American Psychiatric Association. Diagnostic and statistical manual ofmental disorders. 4th ed., text rev.Washington, DC: American Psychiatric Press, 2000.
39. Caraceni A, Nanni O, Maltoni M, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 2000;89:1145-1149
40. Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005;23:6240-6248
41. Trzepacz PT, BreitbartW, Franklin J, et al. Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry 1999;156(5 suppl):1-20.
42. Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics 2002;43:183-194
43. Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000;160:786-794
44. Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry 2003;25:345-352
45. Morita T, Tei Y, Tsunoda J, Inoue S, Chihara S, et al. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage 2001;22:997-1006.
46. Breitbart W, Friedlander M. Confusion/delirium. In: Bruera E, Higginson I, Ripamonti C, von Gunten C, eds. Palliative medicine. London: London Hodder, 2006.
47. Gaudreau JD, Gagnon P, Harel F, Roy MA, Tremblay A. Psychoactivemedications and risk of delirium in hospitalized cancer patients. J Clin Oncol 2005;23:6712-6718
48. Stagno D, Gibson C, Breitbart W. The delirium subtypes: a review of prevalence, phenomenology, pathophysiology, and treatment response. Palliat Support Care 2004;2:171-179
49. Spiller JA,Keen JC. Hypoactive delirium: assessing the extent of the problem for inpatient specialist palliative care. Palliat Med 2006;20:17-23.
50. BreitbartW,Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-237
51. Kiely DK, Jones RN, Bergmann MA, Marcantonio ER. Association between psychomotor activity delirium subtypes and mortality among newly admitted postacute facility patients. J Gerontol A Biol Sci Med Sci 2007;62:174-179
52. Smith M, Breitbart W, Platt M. A critique of instruments and methods to detect, diagnose, and rate delirium. J Pain Symptom Manage 1994;10:35-77.
53. Trzepacz PT: The Delirium Rating Scale: its use in consultation-liaison research. Psychosomatics 1999;40: 193-204.
54. Breitbart W, Rosenfeld B, Roth A. The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997;13: 128-137
55. Lawlor P, Nekolaichuck C, Gagnon B, Mancini I, Pereira J, Bruera E. Clinical utility, factor analysis and further validation of the Memorial Delirium Assessment Scale (MDAS). Cancer 2000;88:2859-2867
56. Inouye SK, Vandyck C, Alessi C. Clarifying confusion: the confusion assessment method, a new method for the detection of delirium. Ann Intern Med 1990;113:941-948
57. Ryan K, Leonard M,Guerin S,Donnelly S, Conroy M, Meagher D. Validation of the confusion assessment method in the palliative care setting. Palliat Med 2009;23:40-45
58. Pitkala KH, Laurila JV, Strandberg TE, Kautiainen H, Sintonen H, Tilvis RS. Multicomponent geriatric intervention for elderly inpatients with delirium: effects on costs and health-related quality of life. J Gerontol A Biol Sci Med Sci 2008;63:56-61.
59. Milisen K, Lemiengre J, Braes T, Foreman MD. Multicomponent intervention strategies for managing delirium in hospitalized older people: systematic review. J Adv Nurs 2005;52:79-90.
60. Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care 2005;3:227-237
61. Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry 2007;68:11-21.
62. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 2007;(2):CD005594.
63. Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev 2004;(2):CD004770.
64. U.S. Food and Drug Administration. Information on antipsychotics. 2009. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm107211.htm
65. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341
66. U.S. Food and Drug Administration. Information for healthcare professionals: haloperidol (marketed as haldol, haldol decanoate and haldol lactate). 2009. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm
67. Lawlor PG, Fainsinger RL, Bruera ED. Delirium at the end of life: critical issues in clinical practice and research. JAMA 2000;284:2427-2429
68. Gagnon B, Low G, Schreier G.Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 2005;30:100-107
69. Keen JC, Brown D. Psychostimulants and delirium in patients receiving palliative care. Palliat Support Care 2004;2:199-202.
70. Morita T, Otani H, Tsunoda J, Inoue S, Chihara S. Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer 2000;8: 134-137
71. Roy-Byrne PP, Davidson KW, Kessler RC, et al. Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry 2008;30:208-225
72. Strain J. Adjustment disorders. In: Holland JC, ed. Psychooncology. New York: Oxford University Press, 1998.
73. Hay JL, McCaul KD, Magnan RE. Does worry about breast cancer predict screening behaviors? A meta-analysis of the prospective evidence. Prev Med 2006;42:401-408
74. Rasic DT, Belik S-L, Bolton JM, Chochinov HM, Sareen J. Cancer, mental disorders, suicidal ideation and attempts in a large community sample. Psychooncology 2008;17:660-667
75. Kangas M, Henry JL, Bryant RA. Correlates of acute stress disorder in cancer patients. J Trauma Stress 2007;20:325-334
76. Palmer SC, Kagee A, Coyne JC, DeMichelle A. Experience of trauma, distress, and posttraumatic stress disorder among breast cancer patients. Psychosom Med 2004;66:258-264
77. Kroll J. Posttraumatic symptoms and the complexity of responses to trauma. JAMA 2003;290:267-270
78. Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329-336
79. Noyes R, Holt CS, Massie MJ. Anxiety disorders. In: Holland JC, BreitbartW, eds. Psycho-oncology. New York: Oxford University Press, 1998.
80. Teunissen SC, de Graeff A, Voest EE, de Haes JC. Are anxiety and depressed mood related to physical symptom burden? A study in hospitalized advanced cancer patients. Palliat Med 2007;21:341-346
81. Stark D, Kiely M, Smith A, Velikova G, House A, Selby P. Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002;20:3137-3148
82. Jackson KC, Lipman AG. Drug therapy for anxiety in palliative care. Cochrane Database Syst Rev 2004;(1):CD004596.
83. Coups EJ, Winell J, Holland JC. Depression in the context of cancer. In: Licinio J, Wong M-L, eds. Biology of depression: from novel insights to therapeutic strategies, vol.1.Weinheim, Germany: Wiley, 2005.
84. Ebrahimi B, Tucker SL, Li D, Abruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma. Cancer 2004;101:2727-2736
85. Laird BJ, Boyd AC, Colvin LA, FallonMT. Are cancer pain and depression interdependent? A systematic review. Psychooncology 2009;18:459-464
86. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-1257
87. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. 2nd ed. Arlington, VA: American Psychiatric Publishing, 2000.
88. Hemaryeck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37.
89. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165:1251-1255
90. Breitbart W. Suicide risk and pain in cancer and AIDS patients. In: Chapman CR, Foley KM, eds. Current and emerging issues in cancer pain: research and practice. New York: Raven, 1993.
91. Kendal WS. Suicide and cancer: a gender-comparative study. Ann Oncol 2007;18:381-387
92. Chochinov HM, Wilson KG, Ennis M, Lander S. Depression, hopelessness, and suicidal ideation in the terminallyill. Psychosomatics 1998;39:336-370
93. Lin HC, Wu CH, Lee HC. Risk factors for suicide following hospital discharge among cancer patients. Psychooncology 2009;18:1038-1044
94. Labisi O. Assessing for suicide risk in depressed geriatric cancer patients. J Psychosoc Oncol 2006;24:43-50. (Pubitemid 44156050)
95. Schairer C, Brown LM, Chen BE, et al. Suicide after breast cancer: an international population-based study of 723,810 women. J Natl Cancer Inst 2006;98:1416-1419
96. Mock V, Atkinson A, Barsevick A, et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 2000;14:151-161
97. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: cancer-related fatigue. Ver. 1. 2009. http://www.nccn.org/ professionals/physiciangls/PDF/fatigue.pdf
98. Mystakidou K, Parpa E, Katsouda E, Galanos A, Vlahos L. The role of physical and psychological symptoms in desire for death: a study of terminally ill cancer patients. Psychooncology 2006;15:355-360
99. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist 2007;12 suppl 1:4-10.
100. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004;(32):40-50.
101. Ahlberg KT, Ekman, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003;362:640-650
102. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998;12:369-377
103. Sadler IJ, Jacobsen PB, Booth-Jones M, Belanger H,Weitzner MA, Fields KK. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 2003;23:406-416
104. Mock V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr 2004;(32):112-118
105. Morrow GR, Shelke AR, Roscoe JA, Hickok JT, Mustian K. Management of cancer related fatigue. Cancer Invest 2005;23:229-239
106. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001;161:411-420
107. Bruera EL, Driver L, Barnes EA. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003;21:4439-4443
108. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006;24: 2073-2078
109. Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004;49:139-144
110. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003;21:4635-4641
111. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966
112. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005;89:243-249
113. Hurria A, Somlo G, Ahles T. Renaming "chemobrain." 2007;25:373-377
114. Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care 2007;5:273-280
115. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in longterm cancer survivors treated with standard-dose chemotherapy. Psychooncology 2003;12:612-619
116. Baider L, Cooper CL, De-Nour AK, eds. Cancer and the family. 2nd ed. Chichester, England: Wiley & Sons, 2000.
117. Ostlund U, Wennman-Larsen A, Persson C, Gustavsson P, Wengstr̈om Y. Mental health in significant others of patients dying from lung cancer. Psychooncology. 2009 Feb 27 [Epub ahead of print].
118. Kissane D, Lichtenthal WG, Zaider T. Family care before and after bereavement. Omega (Westport) 2007-2008;56: 21-32.